Oertel Wolfgang H
Department of Neurology, University Clinic, Philipps Universität Marburg, Marburg, Germany; Institute for Neurogenomics, Helmholtz Center for Health and Environment, Munich, Germany.
F1000Res. 2017 Mar 13;6:260. doi: 10.12688/f1000research.10100.1. eCollection 2017.
This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson's disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) -a methodological challenge to be met in the future.
(1)近期在进一步改善帕金森病(PD)运动症状对症治疗方面取得的成果;(2)在系统寻找PD非运动症状对症治疗方面仍为数不多的尝试;(3)有望对已出现症状的PD进行疾病修饰的化合物在研发和临床试验方面取得的进展。然而,预防(即在前驱期减缓或阻止PD进展)仍是一个梦想,原因之一是我们对反映PD前驱期进展的临床试验主要终点尚无共识,比如在快速眼动睡眠行为障碍(RBD)方面——这是未来有待应对的一项方法学挑战。